๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Objective assessment of motor slowness in Huntington's disease: Clinical correlates and 2-year follow-up

โœ Scribed by Jeroen P.P. van Vugt; Karlijne K.E. Piet; Liesbeth J. Vink; Sabine Siesling; Aeilko H. Zwinderman; Huub A.M. Middelkoop; Raymund A.C. Roos


Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
146 KB
Volume
19
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

Functional disability of patients with Huntington's disease (HD) is determined by impairment of voluntary motor function rather than the presence of chorea. However, only few attempts have been made to quantify this motor impairment. By using a simple reaction time paradigm, we measured the time needed for movement initiation (akinesia) and execution (bradykinesia) in 76 HD patients and 127 controls. Akinesia and bradykinesia were already evident in early stages and increased linearly with increasing disease stage. Quantified motor slowness correlated with clinical impairment of voluntary movements but also with cognitive impairment and medication use. In patients without severe cognitive impairment, quantified motor slowness reflected clinical motor impairment more purely. During 1.9 years followโ€up (range, 0.8โ€“3.8 years), quantified akinesia and bradykinesia progressed concomitantly with progression of clinical impairment of voluntary movements, cognition, and functional capacity. However, rate of change in motor slowness did not discriminate between patients whose disease stage remained stable and those whose disease stage progressed. We conclude that the reaction time paradigm may be used to quantify akinesia and bradykinesia in HD, at least in patients without severe cognitive impairment. Although reaction and movement times increased in time, these measures failed to detect functionally important changes during our followโ€up period. ยฉ 2004 Movement Disorder Society


๐Ÿ“œ SIMILAR VOLUMES


Serum CA 125 is of clinical value in the
โœ Ikram A. Burney; Tariq Siddiqui; Imran Siddiqui ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 30 KB ๐Ÿ‘ 3 views

W e read with interest the article published in Cancer earlier this year regarding the elevation of CA 125 in patients with non-Hodgkin's lymphoma and its normalization with clinical response. 1 Earlier a case report had also emerged about elevation of CA 125 in a patient within tuberculous peritoni

Serum CA 125 is of clinical value in the
โœ Mario Lazzarino; Ester Orlandi; Catherine Klersy; Cesare Astori; Ercole Brusamol ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 116 KB ๐Ÿ‘ 3 views

## Background: Ca 125 is a glycoprotein produced by epithelial ovarian tumors and by mesothelial cells; its levels also have been shown to be elevated in patients with non-hodgkin's lymphoma (nhl). ## Methods: The authors evaluated serum ca 125 levels in patients with nhl to elucidate the frequen